Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Effortless Searching: How to Find Finasteride on Synapse
Drug Insights
2 min read
Effortless Searching: How to Find Finasteride on Synapse
7 February 2024
Finasteride, sold as PROSCAR®, is a 5α-reductase inhibitor mainly used to treat men with benign prostatic hyperplasia (BPH) symptoms with enlarged prostates.
Read →
EMA Reviews GSK's Arexvy RSV Vaccine for Adults 50-59 at High Infection Risk
Latest Hotspot
3 min read
EMA Reviews GSK's Arexvy RSV Vaccine for Adults 50-59 at High Infection Risk
7 February 2024
EMA evaluates GSK's Arexvy, an RSV immunization, for approval to protect adults 50-59 with high risk from RSV infection.
Read →
Making the Most Out of Synapse: Searching for Baclofen
Drug Insights
2 min read
Making the Most Out of Synapse: Searching for Baclofen
7 February 2024
Baclofen, sold under the brand name Lioresal among others, is a medication used to treat muscle spasticity such as from a spinal cord injury or multiple sclerosis.
Read →
EU Commission clears GSK's drug Omjjara (momelotinib) for use
Latest Hotspot
4 min read
EU Commission clears GSK's drug Omjjara (momelotinib) for use
6 February 2024
GSK plc announced the European Commission's approval of Omjjara (momelotinib) for market launch. This daily oral drug inhibits both JAK1/JAK2 and activin A receptor type 1.
Read →
Synapse Simplified: How to Find Ciprofloxacin Information
Drug Insights
2 min read
Synapse Simplified: How to Find Ciprofloxacin Information
6 February 2024
Ciprofloxacin is a fluoroquinolone antibiotic used to treat a number of bacterial infections. It can be taken by mouth, as eye drops, as ear drops, or intravenously.
Read →
Alvotech Reveals Promising Preliminary Results for Potential Prolia® and Xgeva® Equivalent, AVT03
Latest Hotspot
2 min read
Alvotech Reveals Promising Preliminary Results for Potential Prolia® and Xgeva® Equivalent, AVT03
6 February 2024
Alvotech Reveals Encouraging Preliminary Findings from Drug Behavior Analysis of AVT03, a Potential Equivalent to Prolia® and Xgeva®.
Read →
A Complete Guide to Searching Diphenhydramine on Synapse
Drug Insights
2 min read
A Complete Guide to Searching Diphenhydramine on Synapse
6 February 2024
Diphenhydramine (DPH) is an antihistamine and sedative mainly used to treat allergies, insomnia, and symptoms of the common cold.
Read →
FDA Approves Oricell's IND Application for Innovative CAR-T Therapy, OriCAR-017
Latest Hotspot
3 min read
FDA Approves Oricell's IND Application for Innovative CAR-T Therapy, OriCAR-017
6 February 2024
Oricell has received the green light from the FDA for its investigational new drug (IND) application for OriCAR-017, an innovative CAR-T therapy aimed at GPRC5D.
Read →
Using Synapse for Your Tamsulosin Research: An Easy Guide
Drug Insights
2 min read
Using Synapse for Your Tamsulosin Research: An Easy Guide
6 February 2024
Tamsulosin was approved for medical use in the United States in 1997. Specifically it is an α1 adrenergic receptor blocker.
Read →
Sarepta Therapeutics' SRP-5051 Shows Promise in MOMENTUM Phase 2 Trial for Duchenne Muscular Dystrophy
Latest Hotspot
3 min read
Sarepta Therapeutics' SRP-5051 Shows Promise in MOMENTUM Phase 2 Trial for Duchenne Muscular Dystrophy
6 February 2024
Sarepta Therapeutics Reveals Encouraging Results from Segment B in the MOMENTUM Phase 2 Trial for SRP-5051, Targeting Exon 51 Skip-Amenable Duchenne Muscular Dystrophy Cases.
Read →
Accessing Methocarbamol Information on Synapse: A Step-by-Step Approach
Drug Insights
2 min read
Accessing Methocarbamol Information on Synapse: A Step-by-Step Approach
6 February 2024
Methocarbamol, sold under the brand name Robaxin among others, is a medication used for short-term musculoskeletal pain.
Read →
U.S. FDA Clears Takeda's GAMMAGARD LIQUID® for Chronic Inflammatory Nerve Disorder Treatment in Adults
Latest Hotspot
4 min read
U.S. FDA Clears Takeda's GAMMAGARD LIQUID® for Chronic Inflammatory Nerve Disorder Treatment in Adults
6 February 2024
Takeda has disclosed that GAMMAGARD LIQUID®, their intravenous immunoglobulin treatment, has received authorization from the U.S. Food and Drug Administration.
Read →